Encoded Therapeutics has raised $753M across 2 funding rounds, plus 3 undated rounds.
Menlo Ventures backs Encoded Therapeutics, which raised a $104 million Series C and a $135 million Series D round without disclosing a post-money valuation. It has since raised $275 million in Series F financing to advance ETX101 toward pivotal trials.
2 funding rounds, the latest highlighted.
Encoded Therapeutics was founded in 2019, United States.
No date is disclosed for this round.
A primary round — the company sells new shares to investors it selects. $104M raised, led by Menlo Ventures.
No filing has been made.
2 dated rounds, newest first.
GVLEADAanother healthcare fundLEAD
GVLEAD
VenrockLEADAARCH Venture PartnersLEADMMatrix Capital ManagementLEAD
Menlo VenturesLEADRRTW InvestmentsBBoxer CapitalAAlexandria Venture Investments
ARCH VenturesMMatrix CapitalIIllumina VenturesAAltitude Life Science VenturesThe closest gene therapy peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
No. Encoded Therapeutics is a private company; its shares do not trade on a public exchange.
Lead investors for each round are in the funding timeline.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
